menu search

CFRX / Why Is ContraFect (CFRX) Stock Up 23% Today?

Why Is ContraFect (CFRX) Stock Up 23% Today?
ContraFect (NASDAQ: CFRX ) stock is rising higher on Monday as investors react to an update from the Food and Drug Administration (FDA). The FDA has informed ContraFect that it's good to move forward with a Phase 1 clinical trial of CF-370. Read More
Posted: Oct 16 2023, 08:19
Author Name: InvestorPlace
Views: 111189

CFRX News  

Why Is ContraFect (CFRX) Stock Up 23% Today?

By InvestorPlace
October 16, 2023

Why Is ContraFect (CFRX) Stock Up 23% Today?

ContraFect (NASDAQ: CFRX ) stock is rising higher on Monday as investors react to an update from the Food and Drug Administration (FDA). The FDA has more_horizontal

ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023

By GlobeNewsWire
June 8, 2023

ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023

YONKERS, N.Y., June 08, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discover more_horizontal

Why Is ContraFect (CFRX) Stock Down 14% Today?

By InvestorPlace
April 18, 2023

Why Is ContraFect (CFRX) Stock Down 14% Today?

ContraFect (NASDAQ: CFRX ) stock is dropping on Tuesday after the company revealed a notice from the Nasdaq Exchange. That notice has to do with the c more_horizontal

Why Is ContraFect (CFRX) Stock Up 20% Today?

By InvestorPlace
January 31, 2023

Why Is ContraFect (CFRX) Stock Up 20% Today?

ContraFect (NASDAQ: CFRX ) stock is rising higher on Tuesday as investors await news about its potential delisting from the Nasdaq Capital Market. Con more_horizontal

Why Is ContraFect (CFRX) Stock Down 23% Today?

By InvestorPlace
January 27, 2023

Why Is ContraFect (CFRX) Stock Down 23% Today?

ContraFect (NASDAQ: CFRX ) stock is falling on Friday after the company provided an update on its potential delisting from the Nasdaq Capital Market. more_horizontal

Why Is ContraFect (CFRX) Stock Down 80% Today?

By InvestorPlace
July 14, 2022

Why Is ContraFect (CFRX) Stock Down 80% Today?

A Phase 3 trial of ContraFect's treatment for antibiotic-resistant infections has been stopped, and CFRX stock is plunging. The post Why Is ContraFect more_horizontal


Search within

Pages Search Results: